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Methods: We randomly selected an age-stratiﬁed sample of 400 residents from 116 households
in Bamako, Mali, and collected pharyngeal swabs in May 2010. A month later, we enrolled all 202
residents of 20 of these households (6 with known carriers) and collected swabs monthly for 6
months prior to MenAfriVac vaccine introduction and returned 10 months later to collect swabs
monthly for 3 months. We used standard bacteriological methods to identify N. meningitidis
carriers and ﬁt hidden Markov models to assess acquisition and clearance overall and by sex and
age.
Results: During the cross-sectional study 5.0% of individuals (20/400) were carriers. During the
longitudinal study, 73 carriage events were identiﬁed from 1422 swabs analyzed, and 16.3% of
individuals (33/202) were identiﬁed as carriers at least once. The majority of isolates were
non-groupable; no serogroup A carriers were identiﬁed.
Conclusions: Our results suggest that the duration of carriage with any N. meningitidis averages
2.9 months and that males and children acquire and lose carriage more frequently in an urban
setting in Mali. Our study informed the design of a larger study implemented in seven countries
of the African meningitis belt.
© 2017 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Background
The African meningitis belt is an area of increased risk of
bacterial meningitis characterized by distinct seasonal pat-
terns in disease incidence with peaks in the dry season,
large-scale epidemics every 5–12 years, and inter and intra-
annual geographic variation.1–4 This region, which stretches
from Ethiopia in the east to Senegal and The Gambia in the
west, has suffered high morbidity and mortality due to bac-
terial meningitis for more than a century, though rates have
declined in recent years.5–8 N. meningitidis, the bacterial
pathogen primarily responsible for causing meningitis in this
area, is transmitted person-to-person by close contact with
the respiratory droplets or saliva of an infected person. The
bacteria typically live in the pharyngeal passages of healthy
humans without causing symptoms. However, following a
3–7 day incubation period, carriage with N. meningitidis can
lead to invasive disease in some individuals, with high case
fatality. Asymptomatic carriers are relatively common com-
pared to cases of invasive meningococcal disease and are the
primary source of transmission.9,10
A review of meningococcal carriage in the African men-
ingitis belt found that pharyngeal carriage ranged from 3% to
30% across several heterogeneous studies, that carriage is
higher among contacts of cases than in the general popula-
tion, and that carriage dynamics vary due tomultiple context-
speciﬁc factors, many of which are not fully understood.11
Despite knowledge of the key role carriers play in transmis-
sion, relatively little is known about the natural history of
carriers, including the rate of acquisition and clearance of
carriage, and the primary factors that lead from carriage to
invasive disease. These characteristics are especially impor-
tant in epidemiologic contexts where the incidence of inva-
sive disease is high. A greater understanding ofmeningococcal
carriage could provide insight into the epidemiology ofmenin-
gococcal disease including the signiﬁcant geographic and
temporal variation observed in Africa and elsewhere.1 Inves-
tigating carriage could also help inform targeted strategies
for reducing transmission, a top priority for meningococcal
research.12,13
Assessing changes in carriage requires longitudinal studies
that monitor carriage status among the same individuals
over time, yet most carriage studies in Africa have been
cross-sectional. Repeated cross-sectional studies have pro-
vided signiﬁcant insight, indicating that carriage varies little
between seasons14 and that serogroup A carriage prevalence
has declined even further following the introduction of the
conjugatemeningococcal serogroupA vaccine,MenAfriVac.15–17
Longitudinal studies among the same individuals, however,
are more challenging because of the need for long-term
follow-up, the burden of repeated swabbing of the pharyn-
geal passages to determine carrier status, and the low sen-
sitivity of standard culturemethods in detectingmeningococcal
carriage.18 Very few longitudinal studies of N. meningitidis
carriage in Africa had been undertaken prior to this study. A
study in Nigeria in the 1970s found that children were often
the ﬁrst identiﬁed carrier within a household and that the
half-life of carriage was approximately three months.19 In a
more recent study in Burkina Faso, the estimated average
duration of carriage was shorter at 30 days.20 Additional
empirical evidence could increase our understanding of trans-
mission dynamics, inform the design of optimal vaccination
programs to most effectively reduce transmission, and aid in
planning strategies for preventing future outbreaks.
In 2010, prior to the launch of the MenAfriVac mass-
vaccination campaigns across the African meningitis belt,
the African Meningococcal Carriage Consortium (MenAfriCar)
had a unique opportunity to investigate the natural history
of carriage among the general population.21,22 To take advan-
tage of this opportunity, we conducted a longitudinal pilot
study of carriage among residents of Bamako, Mali. Our pilot
study was designed as a prelude to a larger andmore complex
longitudinal carriage study MenAfriCar conduced across seven
countries of the meningitis belt.23
In this pilot study, we aimed to 1) standardize and test
the implementation of clinical and laboratory protocols and
2) assess individual carriage status at multiple time points
over an 18-month period. Our key considerations were to
investigate how high retention in a longitudinal carriage study
following entire households over more than a year would be
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and whether lab and ﬁeld protocols would need to be revised
to ensure high-quality data collection. Households were
recruited for this study because of the close contact within
families in this setting, suggesting that households are a
relevant transmission unit. We aimed to estimate the rate of
acquisition and clearance of carriage, the average duration
of carriage, and whether carriage dynamics differed by sex
and age.
Materials and methods
Study design
Community engagement meetings were held in Bamako, led
by the Center for Vaccine Development-Mali (CVD-Mali), to
provide information to and gain community support for these
research activities from community leaders and representa-
tives prior to the start of MenAfriCar carriage studies.
Cross-sectional screening study
At the outset of our study, we conducted a cross-sectional,
population-based, screening survey in the urban setting of
the Djikoroni-para quartier in Bamako, Mali, in May 2010. We
randomly selected households with at least two members
from the existing demographic surveillance system (DSS) data-
base developed and maintained by CVD-Mali. Within each
household, we randomly selected up to ﬁve participants,
one from each age group (<1 year, 1–4 years, 5–14 years,
15–29 years, and ≥30 years). We continued recruitment until
400 participants had been enrolled: 20 from the youngest
age group; 80 from the second youngest group; and 100 from
each of the remaining groups. Potential participants were
eligible unless they had a serious acute or long-term illness.
Longitudinal household follow-up study
Beginning in July 2010 one month after the cross-sectional
study ended, we selected 20 households from the cross-
sectional study and enrolled all household members (regard-
less of whether the individual has previously participated)
into a follow-up study to identify changes in carrier status
over the next 18 months. All household members from this
subset of selected households were visited every four weeks
July through November 2010 (six visits) by study teams. In
December 2010, the MenAfriVac mass-vaccination campaign
took place in Bamako; all residents aged 1–29 years were
eligible for vaccination. When additional funding became
available, household follow-up resumed 10 months later in
September 2011with visits conductedevery fourweeks through
November 2011 (three visits).
Sample and data collection
According to a standard protocol, at the cross-sectional study
visit and the nine longitudinal study visits, study physicians
collected a single pharyngeal swab using a sterile, dacron-
tipped, plastic shaft swab by swabbing both the posterior
pharynx behind the uvula and one tonsillar fossa.24 Pharyn-
geal swabs were plated immediately in the ﬁeld on Thayer-
Martin (TM) selective agar plates and returned to the laboratory
within six hours. At each visit, participants (or their parents
if they were under 15 years of age) were asked to provide
responses to a survey, administered orally by trained ﬁeld
teams and designed to capture information including demo-
graphics and potential risk factors. At the initial cross-
sectional visit, the head of the household or another adult
also completed a questionnaire to report household charac-
teristics including household size.
Ethical considerations
A community consentmeeting was held prior to study launch,
as noted above. During study recruitment, the head of each
selected household was asked to verbally conﬁrm his or her
agreement for the individual householdmembers to be invited
to participate. Individual participants aged 18 years and
older and parents or guardians of younger children were
asked to providewritten consent after listening to the consent
form read in Bambara, the local language. Those aged 12 to
17 years were asked to provide written assent and children
less than 12 years old provided oral assent. The Ethics Com-
mittees of the University of Bamako Faculty of Medicine and
the London School of Hygiene and Tropical Medicine and the
Institutional ReviewBoard (IRB) of the FredHutchinson Cancer
Research Center approved the data collection and analysis.
TheUniversity ofMinnesota IRBalso approved thedata analysis.
Laboratory analysis
The TM plates were incubated in 5% CO2 at 35–37 °C for up to
72 hours at the CVD-Mali lab. A single colony of typical mor-
phology was selected, sub-cultured on a blood agar plate
(BAP), and incubated for 18–24 hours in 5% CO2 at 35–37 °C
prior to Gram staining and oxidase testing. The colonies
remaining on the TM selective agar plate were collected
with a sterile plastic loop, suspended in a cryotube contain-
ing 1 mL of Brain Heart Infusion (BHI) broth supplemented
with 15% glycerol and stored at –80 °C as a back-up in case
there was a need to go back to the original samples from
study subjects.
Immediately following collection, identiﬁcation of carrier
isolates was undertaken on site using routine microbiologi-
cal culture methods. After all sample collection was com-
pleted, conﬁrmatory analyses indicated that some samples
had been misclassiﬁed. Thus, all samples stored in the BHI
broth from both the cross-sectional and longitudinal visits
were re-analyzed at the Meningococcal Reference Unit at
Public Health England (PHE) to determine N. meningitidis
carrier status. At PHE, the frozen samples were thawed,
sub-culturedonto selectivegonococcalmedia (Oxoid,GCVCAT),
and incubated at 37 °C in 5% CO2 for 18–24 and 48-hour
review. Suspected N. meningitidis colonies were tested with
oxidase reagents and Gram ﬁlm. Any oxidase-positive, Gram-
negative diplococci colonies were sub-cultured for serologi-
cal identiﬁcation, which was undertaken by initial screening
by the dot-blot enzyme-linked immunosorbent assay (ELISA)
(with National Institute for Biological Standards and Control
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monoclonal antibodies (NIBSC mAbs)) for serogroups A, B, C,
Y, and W and/or additional and subsequent use of in-house
polyclonal antibodies utilizing co-agglutination for serogroups
B, C, Y, W, X, E, Z.25
An individual was deﬁned as a positive carrier at a given
visit if N. meningitidis was isolated by PHE from the swab
collected at that visit. All results reported here were based
on laboratory results analyzed at PHE using the microbiologi-
cal and serological methods described above.
Data analysis
Dataweremerged, cleaned andmanaged using STATA version
10 (StataCorp LP 2009) and analyzed using R version 3.3.0.26
Carriage prevalence was summarized by visit at the individ-
ual and household level. Individual time to acquisition and
duration of carriage were estimated from a continuous time
hidden Markov model (HMM) in R using the msm package.27
Due to our interest in assessing the natural history pre-
MenAfriVac introduction and due to the 10-month gap between
the follow up visits conducted in 2010 and 2011 during which
carriage status was unknown, our primary analysis consisted
of ﬁtting the HMM to data from the May 2010 screening and
ﬁrst six monthly follow-up visits through November 2010.
Time was deﬁned as number of days from May 26, 2010, the
ﬁrst day of data collection during the cross-sectional screen-
ing survey. The HMM requires that initial values be supplied
for certain parameters that are estimated during the ﬁtting
process: sensitivity and speciﬁcity were set to 0.8 and 0.9999
respectively; the initial probability of being a carrier was set
equal to the sensitivity for carriers and to (1-speciﬁcity) for
non-carriers; and the initial values in the transition matrix
were estimated by the msm package. The initial values did
not substantially affect the ﬁnal estimates. We also assessed
the acquisition rate per month and whether the duration of
carriage (equivalently, the hazard ratios for acquisition and
clearance) differed by sex and age group (<15 vs. ≥ 15 years
old) by ﬁtting HMMs including these covariates.
Results
During the May 2010 cross-sectional study, 400 participants
from 116 households were enrolled and assessed for carrier
status. Participants ranged from 1 month to 83 years old and
households ranged from 3 to 60 residents. In total, 5% of
individuals from 18 (15.5%) households were identiﬁed as N.
meningitidis carriers.
During the launch of the longitudinal follow-up study in
July 2010, all 202 residents of a subset of 20 of the house-
holds that participated in the cross-sectional study were
invited and enrolled. Based on PHE’s analysis of the swabs,
six of these households had at least one conﬁrmed carrier
identiﬁed during the previous cross-sectional study visit.
Follow-up consisted of six monthly visits conducted in 2010
and three monthly visits conducted in 2011, resulting in 1422
swabs analyzed to determine carrier status during 9 visits
conducted over 18 months. Table 1 describes characteristics
of all participants in the cross-sectional study and of all
participants enrolled in longitudinal follow-up. Table 2 sum-
marizes participation, by visit. The proportion of partici-
pants attending each visit out of the total number of
participants enrolled ranged from 100% (at the ﬁrst follow-up
visit) to 57.4% (at the eighth follow-up visit).
Among the 202 participants that attended at least one of
the ﬁrst six follow-up visits in 2010, 55 carriage events were
identiﬁed from the 1063 swabs analyzed (5.2% of swabs pos-
itive). During this time, 13% of individuals (27/202) were
positive for carriage at least once. Most of the positive car-
riers, 59% (16/27), were observed to carry at more than one
visit. Among the 150 participants who continued to attend at
least one of the three 2011 follow-up visits, 18 carriage
events were identiﬁed from the 354 swabs analyzed (5.1% of
swabs positive). During this time, 7.3% of individuals (11/
150) were positive for carriage at least once. During all of
the follow-up visits, carriage prevalence ranged from a high
of 8.5% of participants during the ﬁrst follow-up visit to a low
of 2.3% during the seventh visit (Fig. 1). The percentage of
households with at least one carrier ranged from a high of
55% during the ﬁrst follow-up visit to a low of 16.7% during
the seventh visit. The longest duration of carriage observed-
i.e., the time period spanned by the longest string of con-
secutive monthly visits where an individual was identiﬁed as
a carrier, including the screening visit, was 4.8 months.
Changes in carriage status over time for all follow-up visits
are shown in Fig. 2.
Based on the hidden Markov model ﬁtted to the data from
all swabs analyzed from the 202 individuals followed during
the cross-sectional study plus the 6 follow-up visits in 2010,
the acquisition rate per month was estimated to be 2.3 per
100 (95% CI: 1.3, 3.8). The mean duration of carriage was
estimated to be 2.9 months (95% CI: 1.6, 5.4). For an indi-
vidual carrier, the probability of clearing carriage within 30
days was 0.282 (95% CI: 0.169, 0.450). The model-based
estimate of the sensitivity of the assay was 0.64 (95% CI:
Table 1 A comparison of the characteristics of individuals
and households that participated in the screening visit (May
2010) and the subsequent follow-up visits (beginning July
2010).
Individual Cross-Sectional
Screening Visit
(n = 400)
First
Longitudinal
Follow-up Visit
(n = 202)
Mean (SD) or
N (%)
Mean (SD) or
N (%)
Age 19.30 (17.56) 22.01 (16.27)
Sex (female) 233 (58) 106 (52)
Sore throat in past week 17 (4) 5 (2)
Cough in past week 92 (23) 31 (15)
Runny nose in past week 133 (33) 57 (28)
Household Screening
visit
(n = 116)
First follow-up
visit
(n = 20)
Mean (SD) or
N (%)
Mean (SD) or
N (%)
Total residents 12.55 (10.09) 13.84 (5.78)
Number of bedrooms 3.98 (1.42) 3.52 (1.68)
With at least one smoker 51 (44) 7 (35)
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0.49, 0.78) and the estimated speciﬁcity was very close to 1.
The results of the hidden Markov model ﬁtted to data col-
lected during all study visits in 2010 and 2011 is given in
Table S1. Acquisition and clearance rates were not signiﬁ-
cantly different between the ﬁrst six follow-up visits and the
three additional 2011 study visits (results not shown).
Table 3 presents the times and hazard ratios for carriage
acquisition and clearance, by sex and age group. Males were
estimated to have acquired carriage at approximately twice
the rate of females (HR = 2.21 [95% CI: 0.66, 7.38]) and
cleared carriage 66% more quickly (HR = 1.66 [95% CI: 0.51,
5.43]), but these differences are not statistically signiﬁcant.
A similar pattern was observed for individuals under age 15,
who were estimated both to acquire and to clear carriage at
approximately twice the rate of individuals aged 15 years
and above, but these differences are also not statistically
signiﬁcant.
From all swabs collected during the screening and all
follow-up visits across the 18 months, we identiﬁed six
serogroup W carrier isolates and nine serogroup Y carrier
isolates. The majority of isolates were classiﬁed as non-
groupable (78/93; 83.9% of isolates). SerogroupWwas carried
Table 2 Proportion of participants attending each visit and proportion where carrier status was assessed for each of the
longitudinal follow-up visits.
Participants Attending Each Visit Carrier Status Assessed
N % of initial
participants
N % of visit
participants
Visit 1: Jul 2010 202 100 201 99.5
Visit 2: Jul/Aug 2010 181 89.6 180 99.4
Visit 3: Aug 2010 179 88.6 177 98.9
Visit 4: Sep/Oct 2010 172 85.1 171 99.4
Visit 5: Oct 2010 166 82.2 165 99.4
Visit 6: Nov 2010 171 84.7 171 100
Dec 2010/Jan 2011 ————- MenAfriVac Campaign ————-
Visit 7: Sep 2011 126 62.4 126 100
Visit 8: Oct 2011 116 57.4 113 97.4
Visit 9: Oct/Nov 2011 118 58.4 118 100
Figure 1 Individual N. meningitidis carriage prevalence observed during each study visit. Dashed vertical bars are 95% exact
binomial conﬁdence intervals calculated under the assumption that carriage is independent across individuals.
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Figure 2 Changes in individual carriage status observed at each follow-up visit. The dashed horizontal lines separate the house-
holds. The gray dots represent the individuals within those households. Enlarged red points represent meningococcal carriers
detected at that visit. Individuals maintain the same vertical position within their household from visit to visit, so persistence of
carriage can be observed by following a single individual horizontally over time.
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by four individuals, (one individual at the cross-sectional
screening visit only, one individual during visit eight only,
and two individuals who both carried during visits eight and
nine). None were in the same household. Serogroup Y was
carried by three individuals (one individual during the screen-
ing visit only, one individual during the screening visit and
visits two, four, and ﬁve, and one individual during visits
one, two, ﬁve, and nine). None were in the same household.
No A, C, or X carriers were identiﬁed.
Discussion
Our evidence suggests that the average duration of menin-
gococcal carriage due to any serogroup in an urban setting in
Mali, a hyperendemic country in the African meningitis belt,
was 2.9 months, and that the estimated rate of acquisition
of carriage was 2.3% per month. The vast majority of carrier
isolates identiﬁed were non-groupable. Males and children
may acquire and clear carriagemore frequently than females
and adults, respectively. Our study was conducted as an
AfricanMeningococcal Carriage (MenAfriCar) Consortiumpilot
study to inform a larger, multi-country study of transmission
of meningococcal carriage within households. Our results
are consistent with the estimated mean duration of carriage
of 3.4 months (95% CI 2.7–4.4) reported in the main study23;
both estimates are lower than the duration of carriage typ-
ically observed in European settings.28–30 The rate of acqui-
sition we report is also similar to the estimated overall rate
of acquisition of meningococci of 2.4% (95% CI 1.6–4.0) per
month estimated in the main study.23
Our pilot study and the main multi-country MenAfriCar
study differed substantially in the number of times each
individual’s carrier status was assessed, the time between
the repeated assessment of carriage among the same
individuals, and the overall length of time during which car-
riagewas assessed. In our study, we assessed carriagemonthly
for 6 months then, following a 10-month gap, monthly for
three months, identifying carriers over an 18-month period.
In the main MenAfriCar study, carriage was assessed twice a
month for two months and then monthly for four months,
identifying carriers over a 6-month period. Yet, it is reassur-
ing that results are remarkably consistent across the two
studies.
Our analysis is limited in that we cannot be certain that
individuals who were found to carry N. meningitidis across
two or more consecutive visits were colonized by the same
isolates. Many N. meningitidis isolates were non-groupable
by serological methods, thus preventing us from assessing
any differences by serogroup. Several previous studies have
also identiﬁed a high proportion of non-groupable carriage
isolates in samples collected in the AfricanMeningitis Belt,31,32
while others have not observed this trend.15,17 While it is not
clear why the proportion of unencapsulated meningococci is
higher in this region than in other regions, one analysis sug-
gested that air humidity may be correlated with acquisition
of non-groupable carrier strains.31 Previous studies have esti-
mated that a lower proportion of carrier isolates are non-
groupable in non-hyperendemic regions such as Europe.33
Additional data and analyses are needed to evaluate
possible causes for the predominance of non-groupablemenin-
gococci in a given geographic and temporal context. Under-
standing the descriptive epidemiology of non-groupable
meningococci is a useful step towards generating hypotheses
and examining possible drivers. In this regard, our study
provides evidence for understanding carriage dynamics in
the African meningitis belt, and is complementary to the
ﬁndings of the larger MenAfriCar carriage study.23 In addi-
tion, we did not account for clustering by household in our
model. Both the results of the pilot study we report here and
the results of the main study highlight the richness of data
that can be obtained through longitudinal studies, compared
to cross-sectional studies alone.
Understanding the natural history of meningococcal car-
riage could have important implications for the prevention
and control of meningococcal disease, especially in highly
endemic areas. Our results and experience led to several
lessons learned, including that conﬁrming identiﬁcation of
carriers rapidly enough to enroll the entire household in
follow-up can be challenging and that either additional efforts
should be undertaken to prevent drop-out after a long period
of study inactivity or that study duration should be kept as
short as possible. These were central to informing the design
and ensuring the success of longitudinal carriage studies
subsequently undertaken in seven sites across the African
meningitis belt by the MenAfriCar Consortium using a modi-
ﬁed design. Our study was designed as a pilot study to dem-
onstrate the feasibility of enrolling entire households in
longitudinal follow-up to assess carrier status, a study design
that has rarely been implemented. We found high participa-
tion rates across many months of follow-up and were able to
identify and address key problems with the initial assess-
ment ofN.meningitidis carrier status. Pilot studies of complex
clinical epidemiological designs are especially important in
low-resource settings where considerable efforts may need
to be undertaken to develop and reﬁne protocols, test data
collection and sample collection tools, and train staff prior
to implementing larger, fully-powered studies.
Table 3 A comparison of the time to acquisition and time to
clearance of carriage by age and sex (along with 95% CIs),
basedonhiddenMarkovmodel results ﬁtted to all data collected
from the 202 participants from the 20 households followed
during the cross-sectional survey plus the 6 follow-up visits in
2010 prior to MenAfriVac introduction.
Hazard ratio
for acquisition
(95% CI)
Hazard ratio
for clearance
(95% CI)
Sex (Males vs.
Females)
2.21 (0.66, 7.38) 1.66 (0.51, 5.43)
Age (≥15 vs.
< 15 years)
0.41 (0.13, 1.32) 0.42 (0.13, 1.36)
Time to
acquisition
in months
(95% CI)
Time to
clearance
in months
(95% CI)
Overall 36.0 (20.6, 63.0) 2.9 (1.6, 5.4)
Males < 15 years 16.1 (6.4, 40.1) 1.6 (0.7, 3.5)
Males ≥ 15 years 39.1 (14.3, 106.9) 3.9 (1.3, 11.5)
Females < 15 years 35.5 (11.4, 110.2) 2.7 (0.9, 8.0)
Females ≥ 15 years 86.3 (27.5, 270.5) 6.4 (1.7, 23.4)
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